Basilea Pharmaceutica is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.
October 17, 2000
Founder: Jan G. J. van de Winkel, Ph.D.
CEO: Ronald Scott
CMO (Medical): Achim Kaufhold
CTO: Günter Ditzinger
CFO: Donato Spota
CSO (Scientific): Laurenz Kellenberger
Please click here for.
Please click here for clinical trial information.